Courtney Rehak

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Miles Miller, Gary Look, Andrew F. Teich, 2014, PloS one.

Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein

G. Rishton, G. Look, N. Izzo, 2020, Journal of neuroscience research.

Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity

H. Levine, N. Izzo, Raymond Yurko, 2020, Journal of neurochemistry.

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

L. Schneider, K. Blennow, Claire Williams, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Gary Look, Ottavio Arancio, Chenbo Zeng, 2014, PloS one.

Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.

G. Rishton, Z. Ni, Jason Zhang, 2021, ACS medicinal chemistry letters.

Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery

N. Izzo, Raymond Yurko, Susan M. Catalano, 2021, Journal of Neuroscience Methods.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

R. Mach, A. Goate, C. Cruchaga, 2014, PloS one.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Miles C. Miller, G. Rishton, O. Arancio, 2014, PloS one.